IRADIMED CORP Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by IRADIMED CORPORATION on July 17, 2017. The filing reports the entry into material definitive agreements regarding amendments to existing warrants to purchase common stock.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the terms of warrant amendments.
Material Changes and Agreements
On July 17, 2017, the Company entered into amendments with three parties regarding warrants originally dated July 21, 2014:
- Roth Capital Partners, LLC: The expiration date of the Roth Warrant was extended to July 17, 2019, in exchange for an increase in the exercise price to $10.05.
- Monarch Capital Group, LLC: The expiration date of the Monarch Warrant was extended to July 17, 2019, in exchange for an increase in the exercise price to $10.05.
- Lisa Walters-Hoffert: The expiration date of the Walters-Hoffert Warrant was extended to July 17, 2019, in exchange for an increase in the exercise price to $10.05.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard qualification that the description of the amendments is subject to the full text of the attached exhibits.
Investor Verification Checklist
- Verify the total number of shares underlying the amended warrants to assess potential dilution at the new $10.05 exercise price.
- Review the full text of Exhibits 10.1, 10.2, and 10.3 for any additional covenants or conditions not summarized in the 8-K.
- Confirm the current market price of IRADIMED common stock relative to the new $10.05 exercise price to determine if the warrants are in-the-money or out-of-the-money.